Lakefront Biotherapeutics (LKFT) Accumulated Expenses (2014 - 2025)

Lakefront Biotherapeutics (LKFT) has reported Accumulated Expenses for 8 consecutive years, with $22759.1 the latest figure, recorded in Q4 2025.

• Quarterly Accumulated Expenses fell 98.17% year-over-year to $22759.1 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $22759.1 (down 98.17% YoY) and the FY2025 annual result came in at $22759.1, down 98.17% from the prior year.
• Accumulated Expenses fell to $22759.1 in Q4 2025 per LKFT's latest filing, from $1.2 million in the prior quarter.
• Over the last five years, Accumulated Expenses for LKFT reached as high as $1.2 million in Q4 2024 and fell as low as $22759.1 in Q4 2025.
• A 3-year average of $629668.0 and a median of $623598.9 in 2023 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2024 — Accumulated Expenses soared 99.27% — and 2025, when it sank 98.17%.
• Year by year, Accumulated Expenses stood at $623598.9 in 2023, then surged by 99.27% to $1.2 million in 2024, then plunged by 98.17% to $22759.1 in 2025.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $22759.1, $1.2 million, and $623598.9 for Q4 2025, Q4 2024, and Q4 2023 respectively.